-+ 0.00%
-+ 0.00%
-+ 0.00%

INNOVENT ANNOUNCES EXPANSION OF GLOBAL PHASE 3 MARSLIGHT-11 STUDY OF IBI363/TAK-928 (ALPHA-BIASED IL-2/PD-1 BISPECIFIC FUSION PROTEIN) IN IMMUNOTHERAPY-RESISTANT NSCLC TO INCLUDE PATIENTS WITH NON-SQUAMOUS NSCLC

Reuters·09/28/2026 00:00:00

Please log in to view news